Lock-up AgreementLock-Up Agreement • January 5th, 2017 • Oncogenex Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Delaware
Contract Type FiledJanuary 5th, 2017 Company Industry JurisdictionThe undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that Achieve Life Science, Inc. (the “Company”) proposes to enter into a Merger Agreement (the “Merger Agreement”) with OncoGenex Pharmaceuticals, Inc. (“Arrow”), Ash Acquisition Sub, Inc., and Ash Acquisition Sub 2, Inc. Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Merger Agreement.
CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • January 5th, 2017 • Oncogenex Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Delaware
Contract Type FiledJanuary 5th, 2017 Company Industry JurisdictionTHIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [●], (this “Agreement”), is entered into by and among OncoGenex Pharmaceuticals, Inc., a Delaware corporation (“Arrow”), Achieve Life Science, Inc., a Delaware corporation (the “Company”), and [●], a [●], as Rights Agent.